Assessing Drug-Smoking Interactions Using PBPK Modeling Blog Assessing Drug-Smoking Interactions Using PBPK Modeling The prevalence of cigarette smoking remains high globally despite abundant evidence showing that it isn't…Certara2016年7月29日
How to Prepare a Study Data Standardization Plan (SDSP) for FDA Blog How to Prepare a Study Data Standardization Plan (SDSP) for FDA Get up-to-speed on Study Data Standardization Plan (SDSP) for FDA submissions. Read the blog post…Certara2016年7月25日
Towards a Best Practice Approach in PBPK Modeling: Case Example of Developing a Unified Efavirenz Model Accounting for Induction of CYPs 3A4 and 2B6 Publication Towards a Best Practice Approach in PBPK Modeling: Case Example of Developing a Unified Efavirenz Model Accounting for Induction of CYPs 3A4 and 2B6 Certara2016年7月20日
Model-based Meta-analysis: An Innovative Methodology Comes of Age White Paper モデルに基づくメタ解析(MBMA):革新的な手法の誕生 MBMA integrates internal and external drug development data to inform proprietary commercial and R&D decisions.…Certara2016年7月14日
D360™ Scientific Informatics Platform for Drug Discovery and Development Brochure D360™ - 創薬開発のための科学情報プラットフォーム Discovery drug research requires understanding complex biological, chemical, logistical and computational data from a wide…Certara2016年7月14日
Phase 1 Study Assessing the Pharmacokinetic Profile and Safety of Avibactam in Patients with Renal Impairment Publication Phase 1 Study Assessing the Pharmacokinetic Profile and Safety of Avibactam in Patients with Renal Impairment Avibactam is a non-β-lactam β-lactamase inhibitor intended for use as a fixed-dose combination with ceftazidime…Certara2016年7月12日
A Tutorial on Pharmacodynamic Scripting Facility in Simcyp Publication A Tutorial on Pharmacodynamic Scripting Facility in Simcyp The Simcyp® Simulator provides a framework for mechanistic Physiologically-Based Pharmacokinetic/Pharmacodynamic modelling of potentially interacting drugs.…Certara2016年7月9日
Status of QSP Modeling in the Pharmaceutical Industry Blog Status of QSP Modeling in the Pharmaceutical Industry A primary cause of failures in pharmaceutical research and development (R&D) has been attributed to…Certara2016年7月6日
Physiologically-based Pharmacokinetic Modeling in Pediatric Oncology Drug Development Publication Physiologically-based Pharmacokinetic Modeling in Pediatric Oncology Drug Development Certara2016年7月1日
More Power to OATP1B1: An Evaluation of Sample Size in Pharmacogenetic Studies Using a Rosuvastatin PBPK Model for Intestinal, Hepatic, and Renal Transporter-mediated Clearances Publication More Power to OATP1B1: An Evaluation of Sample Size in Pharmacogenetic Studies Using a Rosuvastatin PBPK Model for Intestinal, Hepatic, and Renal Transporter-mediated Clearances Rosuvastatin is a substrate of choice in clinical studies of organic anion-transporting polypeptide (OATP)1B1- and…Certara2016年7月1日